Session: 689 ASIP Poster Viewing - Pathobiology of Cardiac Development and Cardiovascular Diseases
(689.12) Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1-deficient adults
Monday, April 4, 2022
11:45 AM – 12:45 PM
Location: Exhibit/Poster Hall A-B - Pennsylvania Convention Center
Presenting Author Imperial College London New Canaan, Connecticut
Biallelic ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency leads to cardiovascular calcification in infancy, FGF23-mediated hypophosphatemic rickets in childhood, and osteomalacia in adulthood. Excessive enthesis mineralization and cervical spine fusion have been previously reported in patients with biallelic ENPP1 deficiency, but their effect on quality of life is unknown. We describe additional musculoskeletal complications in patients with ENPP1 deficiency, namely osteoarthritis and interosseous membrane ossification, and for the first time evaluate health-related quality of life (HRQoL) in patients with this disease, both subjectively via narrative report, and objectively via the Brief Pain Inventory – Short Form, and a Patient Reported Outcome Measurement Information System Physical Function (PROMIS PF) short form. Residual pain, similar in magnitude to that identified in adult patients with X-linked hypophosphatemia, was experienced by the majority of patients despite use of analgesic medications. Impairment in physical function varied from mild to severe. To assess murine ENPP1 deficiency for the presence of enthesopathy, and for the potential response to enzyme replacement therapy, we maintained Enpp1asj/asj mice on regular chow for 23 weeks and treated cohorts with either vehicle or a long-acting form of recombinant ENPP1. Enpp1asj/asj mice treated with vehicle exhibited robust calcification throughout their Achilles tendons, whereas two-thirds of those treated with ENPP1 enzyme replacement exhibited complete or partial suppression of the Achilles tendon calcification. Our combined results document that musculoskeletal complications are a significant source of morbidity in homozygous ENPP1 Deficiency, a phenotype which is closely recapitulated in Enpp1asj/asj mice. Finally, we show that a long-acting form of recombinant ENPP1 prevents the development of enthesis calcification at the relatively modest dose of 0.3 mg/kg per week, suggesting that suppression of enthesopathy may be attainable upon dose escalation.
Jai Ansh was supported by a 2021 ASIP SROPP scholarship. DTB acknowledges support from Inozyme Pharma and the National Institutes of Health (R01 DK121326). CRF was supported in part by the Intramural Research Program of the National Human Genome Research Institute (ZIA HG200407)
(A) Histopathology of Achilles entheses in 23-week-old WT (top) and Enpp1asj/asj mice (bottom) Alizarin Red stain. (B) Histopathology of representative Achilles entheses in 23-week-old Enpp1asj/asj mice treated with weekly subcutaneous injections of 0.3 mg/kg BL-1118. Top – complete responders, middle – partial responders, and bottom – non-responders.; (A) Calcified tissue in Alizarin Red stained sections of WT and Enpp1asj/asj achilles tendon in treated and untreated mice. (B) Calcified tissue in Alizarin Red stained analyzed according to treatment response (CR – complete response; PR – partial response; NR – non-response). Black type - significance between WT and treatment groups. Orange type - significance between treatment groups. ***p < 0.001, ****p < 0.0001 (ANOVA).
